Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Spruce Biosciences (SPRB) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Tralesinidase AlfaMps IiibPhase IIINot Yet RecruitingIntracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)Apr 28, 2026
TildacerfontPolycystic Ovary SyndromePhase IITerminatedA Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal AndrogensMay 06, 2022―
TildacerfontCongenital Adrenal Hyperplasia, 21-OhdPhase IITerminatedA Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAHOct 27, 2021―
Spr001Congenital Adrenal Hyperplasia, Cah - Congenital Adrenal Hyperplasia, Cah - 21-Hydroxylase DeficiencyPhase IICompletedStudy to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal HyperplasiaSep 11, 2018―
Spr001Congenital Adrenal Hyperplasia, Cah - Congenital Adrenal HyperplasiaPhase IICompletedStudy of SPR001 in Adults With Classic Congenital Adrenal HyperplasiaAug 15, 2017―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Spruce Biosciences, Inc. (SPRB) have in its pipeline
Spruce Biosciences SPRB is currently developing the following drugs: Tralesinidase Alfa, Tildacerfont, Spr001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.